cervical brush Cervical cancer is the second-leading cause of cancer mortality among women aged 20–39 years worldwide, causing nine deaths per week in this age group, and the mortality among women in poor counties is twice that of women in affluent counties. In cervical cancer, squamous cell carcinoma is the most common type and accounts for almost 80% of cervical cancer.
[caption id="" align="alignnone" width="629"]
Pregnancy Test Kit[/caption]
Squamous cell cancer generally begins with precancerous lesions, from low squamous intraepithelial lesions to high squamous intraepithelial lesions. cervical brush Current cervical screening programs are used for detecting premalignant lesions to prevent invasive cervical cancer. Since the screening programs have been established, cervical cancer incidence rates have decreased by as much as 80% over the past 40 years in several Western countries As screening with cervical cytology is considered to be an effective method for detecting cervical cancer and precancerous lesions, previous studies have illustrated that the sampling quality is associated with cervical sampling devices, which has resulted in around 60% false-negative results, especially with endogenous cervical cancer The collecting capacity of devices is largely affected by the shape of the device and its material, and a less-than-ideal device ultimately results in false results.
The sampling devices recommended by the European Guidelines for Quality Assurance are the combination of Cytobrush and Ayre spatula, the anatomical spatula, and the Cervix-Brush® Combi A study of the Cervix-Brush Combi indicated that sampling with it resulted in a 2- to the 3-fold harvest of endocervical cells when compared with the Cervex-Brush (10). Another study using the Cervex-Brush® Combi and Cytobrush + Ayres spatula, which included 1,235 patients, showed the specificities were 67.8 and 61.7%, respectively, and there was a better sensitivity for CIN2+ using Cervex-Brush® Combi when the cytology result was HSIL+. However, the Cervix-Brush® Combi is relatively expensive for patients in developing countries.
Based on previous studies, our research group developed a patented cervical brush named the Qi brush (patent ZL 201420720356.8). The Qi brush (Figure 1) consists of endocervical and ectocervical arms with plastic bristles, sheath, and handle. The length of the endocervical arm is 2.0 cm, cervical brush and the length of the bristles is 0.25–0.4 cm from top to near the ectocervical arm. The design of the endocervical arm allows the brush to fit the cervical canal and enable maximum sampling of cells. The ectocervical arm is semilunar and 1.0 cm long, and the length of the bristles is 1.5–2.5 cm from side to the middle. As for the Cervix-Brush® Combi, the endocervical bristle is 1.0 cm long and is composed of short semicircular soft, flexible fibers, and its length is isometric. However, the length of the cervical canal is 2.5–3.0 cm, which implies that an endocervical bristle of the right length might result in more satisfied sampling.
